Drug Profile
Alvelestat - Mereo BioPharma
Alternative Names: AZD-9668; MPH-966Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer Allegheny Singer Research Institute; AstraZeneca; Mereo BioPharma; National Cancer Institute (USA)
- Class Amides; Anti-infectives; Anti-inflammatories; Antibronchitics; Antifibrotics; Antihyperglycaemics; Bronchodilators; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alpha 1-antitrypsin deficiency
Highest Development Phases
- Phase II Alpha 1-antitrypsin deficiency; Type 2 diabetes mellitus
- Phase I/II Bronchiolitis obliterans; COVID-19 respiratory infection
- Discontinued Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 27 Mar 2024 Mereo Biopharma plans a phase III trial for Alpha-1 antitrypsin deficiency by the end of 2024
- 18 Jan 2024 AstraZeneca in collaboration with Mereo Biopharma plans to launch alvelestat for Alpha 1-antitrypsin deficiency in USA (PO), by 2028
- 01 Dec 2023 University of Alabama at Birmingham completes a phase II trial for Alpha 1-antitrypsin deficiency in USA (NCT03679598)